Schlieren ZH/Berlin – Neurimmune and AICURA announce a strategic collaboration to use Artificial Intelligence (AI) for the development of Alzheimer’s therapeutics. The goals are programs for patients and the shortening of development times for drugs.
Schlieren-based Neurimmune AG and AICURA Medical GmbH in Berlin have agreed on a strategic collaboration, according to a press release. They want to use the latest breakthroughs in AI to develop therapeutics for the treatment of Alzheimer's disease. The partnership will use advanced AI systems to design clinical programs with the aim of improving patient outcomes and shortening drug development times, according to identical media releases from both companies.
According to the press release, Neurimmune and AICURA will develop and validate algorithms to predict disease status, response to treatment and potential safety risks. These developments will be based on AICURA's AI capabilities and Neurimmune's expertise in the field of neurodegenerative diseases.
"Artificial intelligence can provide valuable insights to develop targeted therapeutic solutions and guide the clinical development of the next generation of treatments for Alzheimer's patients," Roger M. Nitsch, CEO and Chairman of the Board of Neurimmune, is quoted as saying.
"Neurimmune is pioneering research and clinical development in neurodegenerative diseases with an advancing pipeline of drug candidates and significant, multimodal data sets based on years of clinical research," Daniel Lichterfeld, CEO and founder of AICURA Medical GmbH, is quoted as saying.
Neurimmune was spun off from the University of Zurich in 2006 and is based in the Bio-Technopark Schlieren-Zurich. ce/gba
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Turnstile. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More Information